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Introduction
Th   e third international meeting of the European Network 
for Breast Development and Cancer (ENBDC) again 
promoted the sharing of protocols and ideas between 
groups working on breast development and cancer. 
Graduate students, postdocs and research associates were 
encouraged to attend. Th   e following topics were covered 
in depth: functional screens and sequencing, hormones, 
lineage tracing, the propagation of human breast tumours 
as xenografts and tumour-stroma interactions.
Functional screens and sequencing 
(Chair: Momo Bentires-Alj)
Chris Lord from the Breakthrough Breast Cancer 
Research Centre at the Institute of Cancer Research in 
London presented examples of the power of genome-
wide functional screens. First, his group combined 
tamoxifen treatment of breast cancer cells in vitro and a 
small interfering RNA (siRNA) screen for kinases in an 
approach to identify events leading to tamoxifen 
sensitivity and tamoxifen resistance. Th  ey  identiﬁ  ed low 
cyclin-dependent kinase (CDK)10 expression as an 
important mediator of resistance to endocrine therapy in 
breast cancer. Knockdown of CDK10 blocked its inhibi-
tory eﬀ  ect on ETS2, which in turn induced transcription 
of c-Raf and led to activation of the ERK/mitogen-
activated protein kinase (MAPK) pathway and resistance 
to tamoxifen [1]. Th   ey also used a pooled genome-wide 
small hairpin RNA (shRNA) screen in the presence or 
absence of tamoxifen, coupled with massively parallel 
sequencing, and identiﬁ  ed groups of genes the silencing 
of which increased sensitivity (for example C10orf72, 
C15orf55/NUT,  EDF1,  ING5,  KRAS) or resistance (for 
example,  BAP1,  CLPP,  GPRC5D,  NAE1,  NF1) to 
tamoxifen [2]. Second, they used a synthetic lethal 
unbiased shRNA screen for identifying sensitizers to a 
poly (ADP-ribose) polymerase (PARP) inhibitor in 
BRCA1 wild-type breast cancer cells. Knockdown of 
RAD51D, a novel ovarian cancer susceptibility gene, 
dramatically increased cell death upon PARP inhibition 
[3]. Th  ird, they used a kinome-wide siRNA screen to 
identify genetic dependencies of breast cancer cell lines. 
Characterization of the genetic dependencies of breast 
tumour cell lines with diﬀ  erent tumorigenic mutations 
demonstrated a synthetic lethality between loss of PTEN
and the inhibition of the mitotic checkpoint kinase TTK/
MPS1, which suggests a novel therapeutic approach [4]. 
Th  ese studies warrant further in-depth validation and 
mechanistic studies, which could reveal clinically 
relevant combined therapies or novel targets for cancer.
David Adams from the Wellcome Trust Sanger 
Institute described the eﬀ  orts made by his team to ﬁ  nd 
driver mutations in mouse models of cancer. First, they 
carried out insertion mutagenesis in Apcﬂ  x/+/Ah-Cre mice 
using  Sleeping Beauty insertional mutagenesis tech-
nology, followed by deep sequencing of insertion sites to 
identify genes collaborating with loss of the tumour 
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formation. Th  ey found that inactivation of the H3K4 
methyltransferase  Mll3 induces the Wnt pathway and 
increases tumorigenesis, either alone or in concert with 
loss of Apc [5]. Second, he summarized their eﬀ  orts to 
sequence the genomes of mouse models of breast cancer 
(including models of lobular and basal-like breast 
cancer), which led to the identiﬁ   cation of patterns of 
rearrangement in the diﬀ  erent models and to candidate 
driver cancer genes. Preliminary data on these studies 
have recently been published [6].
Hormones 
(Chairs: María dM Vivanco and Momo Bentires-Alj)
Cathrin Brisken (Swiss Institute for Experimental Cancer 
Research/EPFL Lausanne) spoke on the ‘Genetic dissec-
tion of hormonal control in mammary gland develop-
ment’. Tissue recombination techniques have shown that 
while oestrogen targets the mammary epithelium to 
invoke ductal elongation, progesterone is required for 
ductal side branching. Results from the Brisken lab 
showed that progesterone drives proliferation in two 
waves: ﬁ  rst, cyclin D1 is required for the proliferation of 
some progesterone receptor (PR)+ cells; second, PR- cells 
in particular proliferate through a Receptor activator of 
nuclear factor kappa-B ligand (RANKL)-dependent 
mechanism [7]. Th  ese results highlight the relevance of 
RANKL in the mediation of progesterone function, since 
it rescues the PR-/- phenotype. Importantly, they demon-
strate a key role of progesterone in inducing proliferation 
by a paracrine mechanism. In addition, by modulating 
the expression levels of DeltaNp63 in primary human 
breast epithelial cells, they showed that this transcription 
factor is required to confer a basal cell phenotype. 
Notably, Notch, which reduces DeltaNp63 expression, 
can shift the balance towards a luminal phenotype [8]. 
Furthermore, in vivo ablation of Notch signalling demon-
strated that it is not possible to establish and/or maintain 
luminal cells in the absence of Notch. Th  ese ﬁ  ndings 
reveal antagonistic eﬀ  ects of Notch and p63 on cell fate 
determination in the mammary epithelium.
Maria Vivanco from CIC bioGUNE in Bilbao spoke on 
‘Hormonal regulation in human breast stem cells’ 
focusing on the eﬀ  ects of oestrogen on breast stem cells. 
She showed that expression of the stem cell markers 
Nanog, Oct4 and Sox2 is higher in stem cells isolated 
from normal or breast tumour tissue and can be reduced 
by serum-induced diﬀ   erentiation or treatment with 
oestrogen, whilst tamoxifen had the opposite eﬀ  ect. 
Vivanco further demonstrated that overexpression of 
each individual stem cell gene is suﬃ   cient to increase 
both the number of stem cells, as measured by 
mammosphere formation, aldehyde dehydrogenase 
activity and the cell-surface phenotypes EMA+CALLA+ 
and CD44+CD24-/low, and their invasion capacity; these 
are characteristics of tumourigenesis and poor prognosis 
[9]. Interestingly, this led to reduced oestrogen receptor 
(ER) expression, which is in agreement with the reported 
absence or low expression of ER in breast stem cells. Th  e 
results indicate that oestrogen reduces the pool of breast 
stem cells, providing a plausible explanation for several 
clinical observations, namely that ER+ tumours coincide 
with a better prognosis than ER- tumours, and that 
women on hormone-replacement therapy using oestro-
gen alone have a lower risk of breast cancer than those 
taking oestrogen plus progestin, where the risk is eleva-
ted. Finally, this report emphasised that future therapies 
should combine treatments directed at diminishing 
tumour bulk with new strategies to eliminate cancer stem 
cells whilst sparing normal stem cells [10].
Lineage tracing 
(Chair: John Stingl)
Nick Barker from the Institute of Medical Biology in 
Singapore summarized his work and that of his former 
colleagues in the Hans Clever’s lab on characterizing 
mouse intestinal stem cells. Th  ey demonstrated the 
importance of Wnt as a key regulator of intestinal 
epithelial cell homeostasis. Wnt factors, which are pro-
duced by epithelial cells in the intestinal crypt, are 
essential for Paneth cell diﬀ   erentiation, which in turn 
function as the stem cell niche and also have anti-
microbial properties. Wnt is also a mitogen for transit-
amplifying (TA) cells and for maintaining the intestinal 
stem cell population. Lgr5 (also known as Gpr49), which 
is an orphan G protein-coupled receptor, was identiﬁ  ed 
as a Wnt target gene and found to have a unique 
distribution within the epithelium, with expression 
restricted to basal columnar cells of the crypt. Elegant 
genetic lineage tracing experiments in mice targeting 
Lgr5+ cells revealed the capacity of these cells to maintain 
all of the diﬀ  erent lineages of the intestinal epithelium in 
the long-term, thus fulﬁ  lling the functional requirements 
of intestinal epithelial stem cells. Fate mapping of 
individual stem cells using multicolour reporter mice 
revealed that intestinal stem cells predominantly divide 
symmetrically and that daughter cells stochastically 
adopt stem or TA cell fates. Selective deletion of the 
adenomatous polyposis coli (APC) gene in Lgr5+ cells 
demonstrated that aberrant activation of Wnt signalling 
in these cells causes aggressive adenoma growth 
throughout the intestine. In contrast, loss of APC in TA 
cells resulted only in the generation of microadenomas, 
whose growth rapidly stalled. Th   ese results demonstrate 
the likely stem cell origin of colorectal cancer in this 
mouse model. Interestingly, mouse intestinal tumours 
also contain a minor population of Lgr5+ cells that reside 
in a Paneth cell niche, although it is not clear at this stage 
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Barker also presented data demonstrating that clonal 
outgrowths can be generated and passaged in Matrigel 
cultures in the absence of a cellular stromal niche, and 
that cells from these structures have the potential to 
contribute to the colonic epithelium when introduced 
into suitable recipient mice.
Propagation of human breast tumours as xenografts 
(Chair: John Stingl)
Th   e participants of the meeting were invited to take part 
in a group discussion on the xenotransplantation of 
human breast tumours into immunodeﬁ  cient mice. Th  e 
ability to propagate primary human tumours in mice is a 
powerful tool for studying breast cancer stem cells, as 
well as for breast tumour modelling and other aspects of 
breast cancer cell biology. Unfortunately, human breast 
tumours, particularly those that are ER+, are notoriously 
diﬃ     cult to engraft into mice. During this group dis-
cussion, participants shared their experiences of the 
dissociation and transplantation of human breast tumour 
cells into mice and several factors critical for successful 
engraftment were identiﬁ  ed. Th  ese include (1) minimal 
tissue dissociation in order to minimize the toxicity of 
collagenase over-digestion, (2) the preferred use of NOD 
scid gamma (NSG; NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ JAX) 
mice, (3) co-implantation of cells with Matrigel, and (4) 
patience, since tumour formation may take up to 
6 months.
Tumour-stroma interactions 
(Chair: Rob Clarke)
Akira Orimo (Paterson Institute for Cancer Research, 
University of Manchester, UK) discussed a method that 
allows the experimental generation of cancer-associated 
ﬁ  broblasts (exp-CAFs) from human mammary ﬁ  broblasts 
using a co-implantation tumour xenograft model. Human 
mammary ﬁ   broblasts, co-implanted with breast carci-
noma cells into immunodeﬁ   cient nude mice, were 
extracted from breast tumour xenografts. Th  ese ﬁ  bro-
blasts were shown to increasingly acquire the ability to 
promote carcinoma growth during tumour progression. 
Exp-CAFs also included large numbers of myoﬁ  broblasts, 
which are a hallmark of activated ﬁ  broblasts present in 
wound healing and chronic ﬁ  brosis. Taken together, these 
ﬁ   ndings suggested that exp-CAFs in their tumour-
promoting myoﬁ  broblastic phenotypes resemble primary 
CAFs prepared from breast carcinomas dissected from 
breast cancer patients [11]. Moreover, Orimo demon-
strated that the establishment of autocrine signalling 
loops mediated by transforming growth factor-β and 
stromal cell-derived factor-1 cytokines is responsible for 
the induction and maintenance of CAFs’ tumour-
promoting myoﬁ  broblastic ability, thereby indicating the 
evolution of resident mammary ﬁ  broblasts to tumour-
promoting CAFs during the course of tumour progres-
sion. Th  e roles of exp-CAFs in promoting tumour 
metastasis were also investigated.
Clare Isacke (Breakthrough Breast Cancer Centre, 
London, UK) described approaches to high-throughput 
in vivo RNA interference screens for identifying novel 
determinants of the breast cancer metastatic process. 
Th   e pros and cons of diﬀ  erent biological systems in which 
to conduct a screen, of RNA interference libraries, of the 
methodologies for read-out and analysis, and of diﬀ  erent 
approaches to validate potential hits were described.
Th   e third annual ENBDC methods meeting served as a 
valuable international forum for exchanging protocols 
and ideas relevant to mammary gland development and 
cancer. Th   e 2012 ENBDC methods meeting will be held 
in Weggis on April 13-15 [12].
Abbreviations
ENBDC, European Network for Breast Development and Cancer; ER, oestrogen 
receptor; exp-CAF, experimentally generated cancer-associated fi  broblast; 
PARP, poly (ADP-ribose) polymerase; PR, progesterone receptor; RANKL, 
Receptor activator of nuclear factor kappa-B ligand; shRNA, small hairpin RNA; 
siRNA, small interfering RNA; TA, transit-amplifying.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
The ENBDC workshop was supported by the Friedrich Miescher Institute 
for Biomedical Research (FMI), StemCell Technologies and the KGF 
(Kontaktgruppe für Forschungsfragen) and member companies Roche, 
Novartis, and Merck Serono. MB-A thanks the Swiss Cancer League, the 
European Research Council, the Krebsliga beider Basel and the Novartis 
Research Foundation for support. JS is funded by the University of Cambridge, 
Cancer Research UK and Hutchison Whampoa Limited. MV is supported by 
grants from the Institute of Health Carlos III and the Departments of Education 
and Health of the Government of the Autonomous Community of the Basque 
Country. RBC is a Breast Cancer Campaign-funded Research Fellow in the 
Manchester Breakthrough Breast Cancer Research Unit.
Author details
1CIC bioGUNECell Biology & Stem Cells UnitParque Tecnológico de Bizkaia, Ed 
801A48160 Derio (Bizkaia),Spain. 2Cancer Research UK, Cambridge Research 
Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK. 3Breast 
Biology Group School of Cancer and Imaging Sciences, Paterson Institute 
for Cancer Research, University of Manchester, Wilmslow Road, Manchester 
M20 4BX, UK. 4Friedrich Miescher Institute for Biomedical Research (FMI), 
Maulbeerstr. 66; CH-4058 Basel, Switzerland
Published: 14 October 2011
References
1.  Ior  ns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M, Tutt AN, Crook T, Lord 
CJ, Ashworth A: Identifi  cation of CDK10 as an important determinant of 
resistance to endocrine therapy for breast cancer. Cancer Cell 2008, 
13:91-104.
2.  Men  des-Pereira AM, Sims D, Dexter T, Fenwick K, Assiotis I, Kozarewa I, 
Mitsopoulos C, Hakas J, Zvelebil M, Lord CJ, Ashworth A: Genome-wide 
functional screen identifi  es a compendium of genes aff  ecting sensitivity 
to tamoxifen. Proc Natl Acad Sci U S A 2011 [Epub ahead of print].
3.  Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR, Bowden G, 
Kalmyrzaev B, Warren-Perry M, Snape K, Adlard JW, Barwell J, Berg J, Brady AF, 
Brewer C, Brice G, Chapman C, Cook J, Davidson R, Donaldson A, Douglas F, 
Greenhalgh L, Henderson A, Izatt L, Kumar A, Lalloo F, Miedzybrodzka Z, 
Morrison PJ, Paterson J, Porteous M, et al.: Germline mutations in RAD51D 
del Mar Vivanco et al. Breast Cancer Research 2011, 13:316 
http://breast-cancer-research.com/content/13/5/316
Page 3 of 4confer susceptibility to ovarian cancer. Nature genetics 2011, 43:879-882.
4.  Brough R, Frankum JR, Sims D, Mackay A, Mendes-Pereira AM, Bajrami I, 
Costa-Cabral S, Rafi  q R, Ahmad AS, Cerone MA, Natrajan R, Sharpe R, Shiu KK, 
Wetterskog D, Dedes KJ, Lambros MB, Rawjee T, Linardopoulos S, Reis-Filho 
JS, Turner NC, Lord CJ, Ashworth A: Functional viability profi  les of breast 
cancer. Cancer Discov 2011, 1:260-273.
5.  March HN, Rust AG, Wright NA, ten Hoeve J, de Ridder J, Eldridge M, van der 
Weyden L, Berns A, Gadiot J, Uren A, Kemp R, Arends MJ, Wessels LFA, Winton 
DJ, Adams DJ: Insertional mutagenesis identifi  es multiple networks of 
co-operating genes driving intestinal tumorigenesis. Nature Genetics 2011, 
in press
6.  Var  ela I, Klijn C, Stephens PJ, Mudie LJ, Stebbings L, Galappaththige D, van der 
Gulden H, Schut E, Klarenbeek S, Campbell PJ, Wessels LF, Stratton MR, 
Jonkers J, Futreal PA, Adams DJ: Somatic structural rearrangements in 
genetically engineered mouse mammary tumors. Genome Biol 2010, 
11:R100.
7.  Bel  eut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Choi Y, Schneider 
P, Brisken C: Two distinct mechanisms underlie progesterone-induced 
proliferation in the mammary gland. Proc Natl Acad Sci U S A 2010, 
107:2989-2994.
8.  Yal  cin-Ozuysal O, Fiche M, Guitierrez M, Wagner KU, Raff  oul W, Brisken C: 
Antagonistic roles of Notch and p63 in controlling mammary epithelial 
cell fates. Cell Death Diff  er 2010, 17:1600-1612.
9.  Sim  oes BM, Piva M, Iriondo O, Comaills V, Lopez-Ruiz JA, Zabalza I, Mieza JA, 
Acinas O, Vivanco MD: Eff  ects of estrogen on the proportion of stem cells 
in the breast. Breast Cancer Res Treat 2010, 129:23-35.
10. Viv  anco  M:  Function follows form: defi  ning mammary stem cells. Sci Transl 
Med 2010, 2:31ps22.
11.  Koj  ima Y, Acar A, Eaton EN, Mellody KT, Scheel C, Ben-Porath I, Onder TT, 
Wang ZC, Richardson AL, Weinberg RA, Orimo A: Autocrine TGF-beta and 
stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of 
tumor-promoting mammary stromal myofi  broblasts. Proc Natl Acad Sci U S 
A 2010, 107:20009-20014.
12.  2012 ENBDC methods meeting [www.enbdc.org].
doi:10.1186/bcr3021
Cite this article as: del Mar Vivanco M, et al.: The devil is in the methods: 
lineage tracing, functional screens and sequencing, hormones, tumour-
stroma interactions, and expansion of human breast tumours as 
xenografts. Breast Cancer Research 2011, 13:316.
del Mar Vivanco et al. Breast Cancer Research 2011, 13:316 
http://breast-cancer-research.com/content/13/5/316
Page 4 of 4